Our Pipeline


Program & Drug Pre-Clinical Phase 1 Phase 2 Phase 3 NDA Regions

Oncology

Abivertinib

EGFR T790M+(2nd Line)

China

EGFR mut+(1st Line)

China

Lymphomas

China

AC0002

CNS Tumors

Global

AC0078

FLT3 inhibitor

Global

Autoimmune Disease

AC0058

SLE

Global

Covid-19

Abivertinib

Global
 
Program & Drug Phase Regions
Oncology

Abivertinib

EGFR T790M+(2nd Line)

Phase 2 China

EGFR mut+(1st Line)

Phase 2 China

Lymphomas

Phase 1 China

AC0002

CNS Tumors

Pre-Clinical Global

AC0939

FLT3 inhibitor

Pre-Clinical Global
Autoimmune Disease

AC0058

SLE

Phase 1 Global
Covid-19

Abivertinib

Phase 2 Global